Angio Closes Microsulis Deal - Analyst Blog
February 04 2013 - 5:00AM
Zacks
AngioDynamics Inc.
(ANGO), a provider of therapeutic and diagnostic devices for the
treatment of peripheral vascular and other non-coronary diseases,
completed its previously announced acquisition of certain assets of
Mircosulis Medical Ltd. for $15 million.
According to the agreement, Microsulis’ leading Accu2i pMTA
microwave ablation technology will now be a part of AngioDynamics’
portfolio. The company will also gain the exclusive worldwide
distribution rights for the technology. Further, AngioDynamics
expects to introduce the second generation Accu2i pMTA applicator
in the domestic market.
About Microsulis
Denmead, England-based Microsulis specializes in minimally
invasive, microwave ablation technology for the coagulation of soft
tissues. The medical device company has successfully installed its
systems in over 80 hospitals across the globe.
Microsulis manufactures Accu2i pMTA microwave ablation system with
regulatory clearances in the U.S. as well as in Europe. In Dec
2012, the company’s upgraded Accu2i pMTA applicator also received
the 510(k) clearance from the U.S. Food and Drug Administration
(FDA).
Earlier, in Mar 2012, AngioDynamics and Microsulis entered into a
strategic partnership wherein the former gained the exclusive
overseas distribution rights for the latter’s Accu2i pMTA microwave
ablation system from May 2012 to Dec 2013. The agreement granted
AngioDynamics the exclusive option to purchase all the global
assets and certain liabilities of Microsulis until Sep 2013.
Financial Impact
AngioDynamics made an upfront payment of $10 million. The company
will utilize the cash on hand to pay the remaining $5 million on
Dec 31, 2013. It will also assume up to $1 million of liabilities
of Microsulis. Further, stakeholders at Microsulis might be
entitled to earn-out payments based on its performance over the
next 9 years.
The acquisition is expected to be neutral to AngioDynamics’
adjusted earnings for fiscal 2013. However, the deal will create
value for the company’s shareholders with considerable accretion to
fiscal 2014 adjusted earnings.
Following the acquisition, AngioDynamics will serve a market size
of $250 million for tissue ablation systems. The company expects to
emerge as a pioneer in the global tissue ablation market.
Our Take
We view the acquisition in a positive light based on AngioDynamics’
successful partnership with Micrusulis. The company’s thermal
ablation business has been stagnant for the past three years. In
fiscal 2012, revenues from this franchise stood at $23 million. The
company expects significant revenue synergies from the latest deal,
which is reflected in its annual growth forecast of 20% over the
next 3 years.
Moreover, the buyout is in line with the company’s strategy to grow
on the back of acquisitions and strategic alliances. AngioDyanmics’
aggressive acquisition strategy targets high-growth areas. In Oct
2012, the company acquired Vortex Medical and its coveted Food and
Drug Administration (FDA)-approved Angiovac technology to boost the
peripheral vascular product portfolio.
The company’s current focus on the promising oncology market should
yield positive results. The stock carries a Zacks Rank #3 (Hold).
While we prefer to remain on the sidelines on AngioDyanmics, other
medical stocks such as Merit Medical (MMSI),
Cantel Medical (CMN) and
Cyberonics (CYBX) with Zacks Rank #1 (Strong Buy)
are worth considering.
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
CANTEL MED CORP (CMN): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
MERIT MEDICAL (MMSI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024